🇺🇸 FDA
Patent

US 8273870

Compositions and methods for inhibiting expression of a mutant gene

granted A61PA61P35/00A61P35/02

Quick answer

US patent 8273870 (Compositions and methods for inhibiting expression of a mutant gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61P, A61P35/00, A61P35/02